We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

163 hedge funds and large institutions have $451M invested in Acorda Therapeutics in 2019 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 80 increasing their positions, 39 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

105% more repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 39

51% more call options, than puts

Call options by funds: $1.82M | Put options by funds: $1.21M

11% less funds holding

Funds holding: 184 → 163 (-21)

41% less capital invested

Capital invested by funds: $761M → $451M (-$310M)

51% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 35

Holders
163
Holders Change
-21
Holders Change %
-11.41%
% of All Funds
3.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
80
Reduced
39
Closed
35
Calls
$1.82M
Puts
$1.21M
Net Calls
+$613K
Net Calls Change
+$3.26M

Top Buyers

1
BBA
Baker Bros. Advisors
New York
+$17.6M
2
PA
Perceptive Advisors
New York
+$11.5M
3
Renaissance Technologies
Renaissance Technologies
New York
+$5.6M
4
State Street
State Street
Massachusetts
+$5.35M
5
OAM
Oxford Asset Management
United Kingdom
+$3.06M

Top Sellers

1
SCM
Scopia Capital Management
New York
-$11.6M
2
ClearBridge Investments
ClearBridge Investments
New York
-$8.06M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$6.93M
4
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
-$3.61M
5
OM
Opaleye Management
Massachusetts
-$3.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
SAMH
101
Shanda Asset Management Holdings
British Virgin Islands
$199K – – –
SLF
102
Sun Life Financial
Ontario, Canada
$197K +$134K +109 +104%
MERSOM
103
Municipal Employees' Retirement System of Michigan
Michigan
$187K +$131K +107 +111%
RA
104
Royce & Associates
New York
$185K +$222K +181 +905%
UBS Group
105
UBS Group
Switzerland
$168K -$460K -374 -67%
T. Rowe Price Associates
106
T. Rowe Price Associates
Maryland
$161K +$1.23K +1 +0.6%
MIM
107
MetLife Investment Management
New Jersey
$157K – – –
ProShare Advisors
108
ProShare Advisors
Maryland
$152K -$23.3K -19 -10%
CIM
109
CIM Investment Management
Pennsylvania
$137K -$2.46K -2 -1%
OPERF
110
Oregon Public Employees Retirement Fund
Oregon
$120K +$3.69K +3 +2%
HCMT
111
Highland Capital Management (Texas)
Texas
$119K -$103K -84 -39%
MLICM
112
Metropolitan Life Insurance Company (MetLife)
New York
$112K – – –
AG
113
Aperio Group
California
$108K +$40.6K +33 +39%
GHCM
114
Glen Harbor Capital Management
California
$106K +$33.2K +27 +31%
COPPSERS
115
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$105K +$1.23K +1 +0.9%
SOADOR
116
State of Alaska Department of Revenue
Alaska
$104K +$2.46K +2 +2%
WCM
117
Weld Capital Management
New York
$103K +$136K +111 New
MSA
118
Mason Street Advisors
Wisconsin
$102K +$6.14K +5 +5%
LSERS
119
Louisiana State Employees Retirement System
Louisiana
$99K +$1.23K +1 +0.8%
BMC
120
Benin Management Corp
Connecticut
$90K – – –
MCIM
121
Meadow Creek Investment Management
Georgia
$87K +$27K +22 +30%
Public Employees Retirement Association of Colorado
122
Public Employees Retirement Association of Colorado
Colorado
$84K – – –
XK
123
Xact Kapitalforvaltning
Sweden
$81K – – –
GF
124
Gabelli Funds
New York
$80K +$107K +87 New
TRSOTSOK
125
Teachers Retirement System of the State of Kentucky
Kentucky
$77K – – –
3 4
5
6 7

ACOR Hedge Fund Activity: Q2 2019 in Review

163 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q2 2019, worth a combined $451M — down 41% from $761M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of ACOR and 17 opened new positions — a net loss of 18 holders — while 39 trimmed existing stakes and 80 added.

The largest buyer was Baker Bros. Advisors, adding an estimated $17.6M. The largest seller was Scopia Capital Management, cutting an estimated $11.6M.

  • 163 institutional investors held Acorda Therapeutics (ACOR) as of Q2 2019, down from 184 in Q1 2019.
  • Funds reported $451M of Acorda Therapeutics stock for Q2 2019, down 41% quarter-over-quarter.
  • 17 funds opened new Acorda Therapeutics positions in Q2 2019 and 35 closed out, a net change of -18 holders.
  • The largest Acorda Therapeutics buyer in Q2 2019 was Baker Bros. Advisors, an estimated $17.6M added.
  • The largest Acorda Therapeutics seller in Q2 2019 was Scopia Capital Management, an estimated $11.6M sold.

Based on aggregated 13F filings for Q2 2019.